Navigation Links
Ambit Biosciences To Announce Second Quarter 2014 Financial Results
Date:7/29/2014

SAN DIEGO, July 29, 2014 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced it will report second quarter operational results after closing of the NASDAQ Global Market on Tuesday, August 12, 2014.

A conference call hosted by Michael Martino, president and CEO, and other members of senior management will take place on the same day at 5:00 pm EDT (2:00 pm PDT) and will be webcast live on the Ambit website. 

To access the live teleconference call, dial 866-436-9172 in the U.S. and 630-691-2760 for international callers.  Please specify to the operator that you would like to join the "Ambit Second Quarter 2014 Earnings Conference Call," referencing conference ID number 37609634. If you are unable to listen to the live webcast, a teleconference replay will be available through Tuesday, August 19, 2014.  Interested parties can access the replay by dialing 888-843-7419 and entering the passcode 37609634.

The conference call webcast is accessible through the "Investors & Media" section of the Ambit website at http://www.ambitbio.com.  An online replay will be available following the initial broadcast until Tuesday, September 9, 2014. 

About Ambit Biosciences
Ambit is a biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. Ambit's lead drug candidate, quizartinib (AC220), is a once-daily, orally-administered potent and selective, inhibitor of FMS-like tyrosine kinase-3 (FLT3) and is currently in a registrational Phase 3 clinical trial, referred to as QUANTUM-R, in patients with relapsed/refractory FLT3-ITD positive, acute myeloid leukemia (AML).  Quizartinib is also being studied in newly diagnosed patients in combination with chemotherapy as well as maintenance following a hematopoietic stem cell transplantation (HSCT). In addition to quizartinib, Ambit's clinical pipeline includes AC410, an oral JAK2 inhibitor, and CEP-32496, a BRAF inhibitor licensed to Teva Pharmaceutical Industries Ltd. Ambit's preclinical portfolio includes a proprietary CSF1R inhibitor program.Ambit Contacts: Marcy Graham

Andrew McDonald, Ph.D.Executive Director, Investor Relations & Corp Comm

LifeSci Advisors, LLCAmbit Biosciences Corporation

Founding Partner858-334-2125

646-597-6987mgraham@ambitbio.com

andrew@lifesciadvisors.com  


'/>"/>
SOURCE Ambit Biosciences
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Ambit Announces Presentations At The 55th Annual Meeting Of The American Society Of Hematology (ASH)
2. Ambit Announces Participation At Oppenheimer 24th Annual Healthcare Conference
3. Ambit Biosciences Provides Regulatory Update Following FDA Meeting Regarding Quizartinib (AC220)
4. Ambit Biosciences to Announce Third Quarter 2013 Financial and Operating Results and Conference Call
5. Ambit Biosciences Corporation Announces Second Quarter 2013 Operational Results
6. Ambit Biosciences to Announce Second Quarter 2013 Operational Results and Conference Call
7. Ambit Biosciences Announces Presentations of Data from Clinical Investigations of Quizartinib at the Annual Meeting of the American Society of Clinical Oncology
8. Lo studio pubblicato su European Radiology esalta ulteriormente lutilizzo della tomosintesi al seno di Hologic nellambito dello screening del cancro con utilizzo della doppia lettura
9. Ambit Biosciences Appoints David Parkinson, M.D., to Board of Directors
10. Astellas and Ambit to End Collaboration for Joint Development and Commercialization of FLT3 Kinase Inhibitors
11. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2017)... , July 13, 2017 RK Logistics Group, ... of Pharmacy certification for its Fremont, CA ... solutions in the Tri-Valley and San Jose ... City of Fremont , with its Fremont Innovation ... to provide such a powerful resource to the hundreds of ...
(Date:7/12/2017)... INDIANAPOLIS , July 12, 2017  Eli Lilly and ... settlement agreement with generic companies to resolve pending patent litigation ... Virginia regarding the Cialis ® ... expire on April 26, 2020. As part of the agreement, ... on September 27, 2018. "The unit dose patent ...
(Date:7/11/2017)... 2017  The global market for liquid biopsy diagnostic ... million in 2016.  Although in early stages, the global ... particular as a result of the gradual shift towards ... introduction of a significant number of new liquid biopsy ... tumor biomarkers to guide treatment decisions. ...
Breaking Medicine Technology:
(Date:7/25/2017)... ... July 25, 2017 , ... Therachat , a smart ... and providing demos of its smart journaling platform at the 125th American Psychological ... D.C. from August 3-6, 2017. , The APA Annual Convention is one of ...
(Date:7/25/2017)... WI (PRWEB) , ... July 25, 2017 , ... ... Aloria Health, as medical director. Dr. Negrette has more than a decade of ... She has worked closely with individuals fighting addictions, eating disorders, psychotic and manic ...
(Date:7/25/2017)... TX (PRWEB) , ... July 25, 2017 , ... SignatureCare ... emergencies in the Austin, TX area 24 Hours a day. , The ... Austin, TX. , “We’ve been open four months now and things are running ...
(Date:7/24/2017)... ... 2017 , ... Cheerag D. Upadhyaya , M.D., M.Sc., FAANS has been ... (SLMBNI), part of Saint Luke’s Health System . Dr. Upadhyaya has served in ... M.Sc., FAANS joins Stanley P. Fisher, M.D., who has served as medical ...
(Date:7/24/2017)... ... July 24, 2017 , ... BayMark Health Services ... Health Services Administration’s (SAMHSA) State Targeted Response to the Opioid Crisis program. ... will facilitate the development of a hub and spoke model for opioid treatment ...
Breaking Medicine News(10 mins):